1 unchanged sentence
(c) Director and Officer Trading Arrangements
−Removed: None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5 -1 trading arrangement (as such terms are defined in Items 408(a) and 408(c) of Regulation S-K, respectively) during the quarterly period covered by this report.
+Added: A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act,” is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or our other securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, for diversification or other personal reasons.
+Added: Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S.
+Added: federal securities laws that prohibit trading while in possession of material nonpublic information.
+Added: Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
+Added: The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a non-Rule 10b5-1 trading arrangement, as defined in Item 408(c) of Regulation S-K.
+Added: Duration of Trading
+Added: (Date of Action)
+Added: Todd Carter, Ph.D.
+Added: (Chief Scientific Officer)
+Added: ( September 9, 2024 )
+Added: Rule 10b5-1 trading arrangement for exercises of options and sales of shares
+Added: Until August 15, 2025, or such earlier date upon which all transactions are completed or expire without execution
+Added: Up to 79,000 shares
The exhibits filed or furnished as part of this Quarterly Report are set forth on the Exhibit Index, which is incorporated herein by reference.
1 unchanged sentence
Incorporated by Reference to:
−Removed: First Amendment to Collaboration Agreement, by and between Registrant and Neurocrine Biosciences, Inc., dated April 3, 2024.
−Removed: Employment Agreement, by and between the Registrant and Nathan Jorgensen, Ph.D., dated as of June 11, 2024.
+Added: First Amendment to Option and License Agreement, by and between Registrant and Novartis Pharma AG, dated S eptember 3 , 2024.
+Added: First Amendment to Option and License Agreement, by and between Registrant and AstraZeneca Ireland Limited, dated September 30, 2024.
Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14 or 15d-14.
12 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: August 6, 2024
+Added: November 12, 2024
VOYAGER THERAPEUTICS, INC.
8 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.